Abstract
No public abstract is available from the verified source records.
Simon A Brown, Louis M. Aledort, Christine A. Lee, T W Barrowcliffe, Karen Beeton, Victor S. Blanchette, Bolland, S, Goddard, N, Anne C. Goodeve, Leon W. Hoyer, Kessler, C, Rolf C. R. Ljung, Pete Lollar, Marilyn J. Manco‐Johnson, G. Mariani, C Peerlinck, Georges‐Étienne Rivard
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.3109/ort.1965.36.suppl-77.01
10.3109/ort.1965.36.suppl-77.01
10.1111/j.1365-2796.1992.tb00546.x
10.1111/j.1365-2796.1992.tb00546.x
10.1111/j.1365-2796.1994.tb00815.x
10.1111/j.1365-2796.1994.tb00815.x
10.1046/j.1365-2516.2000.00427.x
10.1046/j.1365-2516.2000.00427.x
10.1046/j.1365-2141.1996.420960.x
10.1046/j.1365-2141.1996.420960.x
10.1046/j.1365-2141.1999.01463.x
10.1046/j.1365-2141.1999.01463.x
10.1046/j.1365-2516.2000.00439.x
10.1046/j.1365-2516.2000.00439.x
Prevention and treatment of factor VIII inhibitors in murine hemophilia A
10.1182/blood.v95.4.1324.004k25_1324_1329 · 2000
10.1084/jem.192.5.681
10.1084/jem.192.5.681
Characterization of factor VIII B‐cell inhibitory epitopes
10.1055/s-0037-1615872 · 1999
Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply‐substituted hybrid human/porcine factor VIII molecules
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1182/blood.v95.2.564 · 2000
10.1182/blood.v97.1.169
10.1182/blood.v97.1.169
Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM)
10.1055/s-0037-1613931 · 2000
Factor‐VIII gene inversions in severe haemophilia‐A – results of an international consortium study
10.1182/blood.v86.6.2206.bloodjournal8662206 · 1995
10.1055/s-0038-1649954
10.1055/s-0038-1649954
10.1111/j.1365-2516.1996.tb00006.x
10.1111/j.1365-2516.1996.tb00006.x
10.1046/j.1365-2516.1998.440574.x
10.1046/j.1365-2516.1998.440574.x
10.1073/pnas.83.23.9169
10.1073/pnas.83.23.9169
10.1097/00043426-199701000-00003
10.1097/00043426-199701000-00003
10.1182/blood.v89.3.1115
10.1182/blood.v89.3.1115
10.1007/s004670050522
10.1007/s004670050522
10.1016/s1074-7613(00)00027-3
10.1016/s1074-7613(00)00027-3
10.1002/ajh.2830170111
10.1002/ajh.2830170111
10.1080/080352598750031365
10.1080/080352598750031365
10.1055/s-0038-1646162
10.1055/s-0038-1646162
Comparison of bleeding tendency, factor XI coagulant activity and factor XI antigen in 25 factor XI‐deficient kindreds
10.1182/blood.v65.3.719.719 · 1985
10.1111/j.1365-2516.1995.tb00080.x
10.1111/j.1365-2516.1995.tb00080.x
Platelet von Willebrand factor: an important determinant of the bleeding time in type 1 von Willebrand’s disease
10.1182/blood.v68.1.58.58 · 1986
Comparison of four virus‐inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross over randomized trial
10.1182/blood.v79.12.3130.bloodjournal79123130 · 1992
10.1111/j.1365-2516.1996.tb00018.x
10.1111/j.1365-2516.1996.tb00018.x
10.2106/00004623-199404000-00002
10.2106/00004623-199404000-00002
10.1002/9780470693872.ch12
10.1002/9780470693872.ch12
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.